In addition to HER2 protein overexpression or gene amplification, other predictive biomarkers have been reported for patients with HR+/HER2+ breast cancer, including gene expression scores, DNA mutations, proliferation, and the immune microenvironment (Dieci et al. 2020). The gene discussed is ERBB2; the disease is breast carcinoma.